KRAS and cancer: A current clinical trial (ClinicalTrials.gov), for example, is testing trametinib in combination with ponatinib, a multityrosine kinase inhibitor (FDA-approved for both chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia) therefore indicating that combinational therapies using drugs already approved for other cancer types, could be promising when combined for the treatment in K-RAS mutant NSCLC.